Technical Analysis for INBX - Inhibrx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | -0.03% | |
| 20 DMA Resistance | Bearish | -0.87% | |
| MACD Bullish Signal Line Cross | Bullish | -0.87% | |
| Pocket Pivot | Bullish Swing Setup | -0.87% | |
| Gapped Up | Strength | -0.87% | |
| Inside Day | Range Contraction | -0.12% | |
| Shooting Star Candlestick | Bearish | -0.47% | |
| Slingshot Bearish | Bearish Swing Setup | -0.47% | |
| Lower Bollinger Band Walk | Weakness | -0.47% | |
| Lizard Bullish | Bullish Day Trade Setup | -0.18% |
| Alert | Time |
|---|---|
| Outside Day | 19 minutes ago |
| Fell Below Previous Day's Low | 19 minutes ago |
| Gap Up Closed | 34 minutes ago |
| Reversed from Up | 34 minutes ago |
| 10 DMA Support | about 5 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.79 |
| 52 Week Low | 14.305 |
| Average Volume | 489,999 |
| 200-Day Moving Average | 27.22 |
| 50-Day Moving Average | 35.26 |
| 20-Day Moving Average | 34.48 |
| 10-Day Moving Average | 34.16 |
| Average True Range | 0.48 |
| RSI (14) | 37.50 |
| ADX | 24.8 |
| +DI | 12.93 |
| -DI | 18.96 |
| Chandelier Exit (Long, 3 ATRs) | 33.97 |
| Chandelier Exit (Short, 3 ATRs) | 35.18 |
| Upper Bollinger Bands | 35.19 |
| Lower Bollinger Band | 33.76 |
| Percent B (%b) | 0.17 |
| BandWidth | 4.15 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.32 |
| MACD Histogram | 0.0093 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.81 | ||||
| Resistance 3 (R3) | 34.86 | 34.65 | 34.67 | ||
| Resistance 2 (R2) | 34.65 | 34.45 | 34.62 | 34.63 | |
| Resistance 1 (R1) | 34.33 | 34.32 | 34.23 | 34.28 | 34.58 |
| Pivot Point | 34.12 | 34.12 | 34.07 | 34.09 | 34.12 |
| Support 1 (S1) | 33.80 | 33.92 | 33.70 | 33.75 | 33.44 |
| Support 2 (S2) | 33.59 | 33.79 | 33.56 | 33.39 | |
| Support 3 (S3) | 33.27 | 33.59 | 33.35 | ||
| Support 4 (S4) | 33.22 |
